Annaratone L, Cascardi E, Vissio E et al (2020) The multifaceted nature of tumor microenvironment in breast carcinomas. Pathobiology 87:125–142

Article  PubMed  CAS  Google Scholar 

Bianchini G, De Angelis C, Licata L, Gianni L (2021) Treatment landscape of triple-negative breast cancer — expanded options, evolving needs. Nat Rev Clin Oncol 19:91–113

Article  PubMed  Google Scholar 

Brewster AM, Chavez-MacGregor M, Brown P (2014) Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol 15:e625–e634

Article  PubMed  PubMed Central  Google Scholar 

Chen Q, He L, Li X et al (2022) Ruthenium complexes boost NK cell immunotherapy via sensitizing triple-negative breast cancer and shaping immuno-microenvironment. Biomaterials 281:121371

Article  PubMed  CAS  Google Scholar 

Corti C, Giugliano F, Nicolò E et al (2023) HER2-low breast cancer: a new subtype? Curr Treat Options Oncol 24:468–478

Article  Google Scholar 

Derakhshan F, Reis-Filho JS (2022) Pathogenesis of triple-negative breast cancer. Annu Rev Pathol Mech Dis 17:181–204

Article  CAS  Google Scholar 

Efil SC, Guner G, Guven DC et al (2023) Prognostic and predictive value of tumor infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer. Clin Res Hepatol Gastroenterol 47:102171

Article  PubMed  CAS  Google Scholar 

Geurts V, Kok M (2023) Immunotherapy for metastatic triple negative breast cancer: current paradigm and future approaches. Curr Treat Options Oncol 24:628–643

Article  PubMed  PubMed Central  Google Scholar 

Heist RS, Sands J, Bardia A et al (2024) Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 125:102720

Article  PubMed  CAS  Google Scholar 

Hong R, Xu B (2022) Breast cancer: an up-to‐date review and future perspectives. Cancer Commun 42:913–936

Article  Google Scholar 

Hu Q, Hong Y, Qi P et al (2021) Atlas of breast cancer infiltrated B-lymphocytes revealed by paired single-cell RNA-sequencing and antigen receptor profiling. Nat Commun 12

Huertas-Caro CA, Ramirez MA, Gonzalez-Torres HJ et al (2022) Immune lymphocyte infiltrate and its prognostic value in triple-negative breast cancer. Front Oncol 12

Hutchinson L (2014) TNBC: can we treat the untargetable? Nat Rev Clin Oncol 11:379–379

Article  PubMed  Google Scholar 

Lin C-J, Xiao W-X, Fu T et al (2023) Calcifications in triple-negative breast cancer: molecular features and treatment strategies. Npj Breast Cancer 9

Liu Y, Hu Y, Xue J et al (2023) Advances in immunotherapy for triple-negative breast cancer. Mol Cancer 22

Matovina-Brko G Spopovicl, Popovic M et al (2023) Targeting triple-negative breast cancer: a clinical perspective. Oncol Res 31:221–238

Article  PubMed  PubMed Central  Google Scholar 

Rugo HS, Bardia A, Marmé F et al (2022) Sacituzumab govitecan in hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer. JCO 40:3365–3376

Article  CAS  Google Scholar 

Sha S, Si L, Wu X et al (2022) Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer. Front Immunol 13

Shepherd JH, Ballman K, Polley M-YC et al (2022) CALGB 40603 (Alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer. JCO 40:1323–1334

Article  CAS  Google Scholar 

Shiao SL, Gouin KH III, Ing N et al (2024) Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer. Cancer Cell 42:70–84e8

Article  PubMed  CAS  Google Scholar 

So JY, Ohm J, Lipkowitz S, Yang L (2022) Triple negative breast cancer (TNBC): non-genetic tumor heterogeneity and immune microenvironment: emerging treatment options. Pharmacol Ther 237:108253

Article  PubMed  PubMed Central  CAS  Google Scholar 

Székely B, Silber ALM, Pusztai L (2017) New therapeutic strategies for triple-negative breast cancer. Oncol (Williston Park) 31:130–137

Google Scholar 

van den Ende NS, Nguyen AH, Jager A et al (2023) Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review. IJMS 24:2969

Article  PubMed  PubMed Central  Google Scholar 

Wang XQ, Danenberg E, Huang C-S et al (2023) Spatial predictors of immunotherapy response in triple-negative breast cancer. Nature 621:868–876

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wu D, Zhou R, Chen H et al (2024) The role of traditional Chinese medicine in the management of cervical cancer. Am J Chin Med 52:1013–1025

Article  PubMed  CAS  Google Scholar 

Xia C, Dong X, Li H et al (2022) Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J 135:584–590

Article  PubMed  PubMed Central  Google Scholar 

Xiao C, Zhao X, Li X et al (2022a) Classification of colorectal cancer into clinically relevant subtypes based on genes and mesenchymal cells. Clin Transl Oncol 25:491–502

Article  PubMed  Google Scholar 

Xiao Y, Ma D, Yang Y-S et al (2022b) Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. Cell Res 32:477–490

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yang X, Zhang B (2023) A review on crispr/cas: a versatile tool for cancer screening, diagnosis, and clinic treatment. Funct Integr Genomics 23

Yang F, Xiao Y, Ding J-H et al (2023) Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell Metabol 35:84–100e8

Article  CAS  Google Scholar 

Yap TA, Bardia A, Dvorkin M et al (2023) Avelumab plus talazoparib in patients with advanced solid tumors. JAMA Oncol 9:40

Article  PubMed  Google Scholar 

Ye L, Zhong F, Sun S et al (2023) Tamoxifen induces ferroptosis in MCF-7 organoid. J Cancer Res Ther 19:1627–1635

Article  PubMed  CAS  Google Scholar 

Yu T, Di G (2017) Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance. Chin J Cancer Res 29:237–252

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhu S, Wu Y, Song B et al (2023) Recent advances in targeted strategies for triple-negative breast cancer. J Hematol Oncol 16

Zou Y, Xie J, Zheng S et al (2022) Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery. Int J Surg 107:106936

Article  PubMed  Google Scholar